{"id":"NCT02725411","sponsor":"Pfizer","briefTitle":"Long Term Safety and Efficacy Study of Tanezumab in Japanese Adult Subjects With Chronic Low Back Pain","officialTitle":"A PHASE 3 RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED, MULTICENTER STUDY OF THE LONG-TERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN JAPANESE ADULT SUBJECTS WITH CHRONIC LOW BACK PAIN","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-05-26","primaryCompletion":"2019-06-11","completion":"2019-06-11","firstPosted":"2016-04-01","resultsPosted":"2020-08-11","lastUpdate":"2020-08-11"},"enrollment":277,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Low Back Pain"],"interventions":[{"type":"DRUG","name":"Celecoxib","otherNames":[]},{"type":"BIOLOGICAL","name":"Tanezumab 5 mg","otherNames":[]},{"type":"BIOLOGICAL","name":"Tanezumab 10 mg","otherNames":[]},{"type":"DRUG","name":"Placebo for celecoxib","otherNames":[]},{"type":"BIOLOGICAL","name":"Placebo for tanezumab","otherNames":[]}],"arms":[{"label":"Celecoxib","type":"ACTIVE_COMPARATOR"},{"label":"Tanezumab 5 mg","type":"EXPERIMENTAL"},{"label":"Tanezumab 10 mg","type":"EXPERIMENTAL"}],"summary":"This study will investigate the long-term safety and efficacy of a fixed dose of tanezumab 5 mg and 10 mg administered subcutaneously (SC) seven times at 8 week intervals. The primary objective of this study is to evaluate the long term safety of tanezumab 5 mg and 10 mg administrated SC every 8 weeks (7 administrations). In addition, the study will evaluate the long term analgesic efficacy of tanezumab 5 mg and 10 mg SC administered every 8 weeks (7 administrations).","primaryOutcome":{"measure":"Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)","timeFrame":"Baseline (Day 1) up to 24 weeks after last dose of study drug (up to Week 80)","effectByArm":[{"arm":"Tanezumab 5 mg","deltaMin":70,"sd":null},{"arm":"Tanezumab 10 mg","deltaMin":63,"sd":null},{"arm":"Celecoxib","deltaMin":67,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":32},"locations":{"siteCount":55,"countries":["Japan"]},"refs":{"pmids":["34786956"],"seeAlso":["https://pmiform.com/clinical-trial-info-request?StudyID=A4091063"]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":92},"commonTop":["Nasopharyngitis","Arthralgia","Back pain","Fall","Hypoaesthesia"]}}